CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Open access
Husain, Mansoor, Consoli, Agostino, De Remigis, Alessandra, Pettersson Meyer, Anna Sina, Rasmussen, Søren, Bain, Stephen · 2022 · Cardiovascular Diabetology

Abstract

Background: Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to baseline metformin use. Methods: A post hoc analysis was conducted using pooled SUSTAIN 6 and PIONEER 6 CVOT data in subjects with and without metformin use at baseline. Additionally, a trial-level meta-analysis was conducted using data from seven CVOTs with GLP-1RAs–SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER, REWIND, EXSCEL and AMPLITUDE-O–including adults with type 2 diabetes at high CV risk, and a primary endpoint of time to first major adverse CV event (MACE). Results: In the post hoc analysis, the no-metformin subgroup was older, with a higher body mass index, lower estimated glomerular filtration rate and higher CV risk at baseline vs the metformin subgroup. Hazard ratios (95% confidence intervals) for the reduction in risk of MACE with semaglutide vs placebo in the metformin and no-metformin subgroups were 0.70 (0.55;0.89) and 0.86 (0.60;1.22), respectively. No significant interaction between the treatment effect on MACE and metformin subgroup was observed. Findings for other CV endpoints were similar. In the meta-analysis, treatment effect (GLP-1RA vs placebo) on CV outcomes was no different with vs without baseline metformin (overall ratio between the hazard ratios for metformin vs no-metformin 1.09 [0.96;1.22]). Conclusion: These findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs. Trial registration SUSTAIN 6 (NCT01720446), PIONEER 6 (NCT02692716).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-022-01489-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CV risk score* according to metformin use at baseline. The light gray color indicates the overlap between the metformin and no-metformin subgroups. *Derived from a prediction model developed using independent data sets from the liraglutide CV outcomes trial and previously applied to SUSTAIN 6 and PIONEER 6 [19]. CV cardiovascular
Fig. 1 CV risk score* according to metformin use at baseline. The light gray color indicates the overlap between the metformin and no-metformin subgroups. *Derived from a prediction model developed using independent data sets from the liraglutide CV outcomes trial and previously applied to SUSTAIN 6 and PIONEER 6 [19]. CV cardiovascularCC BY · PubMed Central
Fig. 2 A CV outcomes/mortality by baseline metformin use (adjusted analysis); B Kaplan–Meier curves of primary outcome by baseline metformin. Figures (A) and (B) compare semaglutide with placebo. *n-numbers are based on the FAS; the number of subjects included for each endpoint analysis differed according to data availability. A Analyses for SUSTAIN 6 and PIONEER 6 are based on a Cox proportional hazards model with treatment (semaglutide, placebo) by metformin subgroup as fixed factors, stratified by trial and CV risk group (established CVD and/or CKD vs risk factors), and adjusted by baseline variables: sex (male vs female), smoker (current smoker, previous smoker, never smoked), previous MI/stroke/TIA (yes vs no), region (European Union, North America, other), antidiabetic treatment (yes vs no), diabetes duration, eGFR-MDRD and age. CI confidence interval, CKD chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, eGFR-MDRD estimated glomerular filtration rate-modification of diet in renal disease, FAS full analysis set, HbA1c glycated hemoglobin, HHF hospitalization for heart failure, HR hazard ratio (semaglutide vs placebo), MACE major adverse cardiovascular event, MET metformin, MI myocardial infarction, TIA transient ischemic attack
Fig. 2 A CV outcomes/mortality by baseline metformin use (adjusted analysis); B Kaplan–Meier curves of primary outcome by baseline metformin. Figures (A) and (B) compare semaglutide with placebo. *n-numbers are based on the FAS; the number of subjects included for each endpoint analysis differed according to data availability. A Analyses for SUSTAIN 6 and PIONEER 6 are based on a Cox proportional hazards model with treatment (semaglutide, placebo) by metformin subgroup as fixed factors, stratified by trial and CV risk group (established CVD and/or CKD vs risk factors), and adjusted by baseline variables: sex (male vs female), smoker (current smoker, previous smoker, never smoked), previous MI/stroke/TIA (yes vs no), region (European Union, North America, other), antidiabetic treatment (yes vs no), diabetes duration, eGFR-MDRD and age. CI confidence interval, CKD chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, eGFR-MDRD estimated glomerular filtration rate-modification of diet in renal disease, FAS full analysis set, HbA1c glycated hemoglobin, HHF hospitalization for heart failure, HR hazard ratio (semaglutide vs placebo), MACE major adverse cardiovascular event, MET metformin, MI myocardial infarction, TIA transient ischemic attackCC BY · PubMed Central
Fig. 3 Metabolic and safety outcomes with semaglutide vs placebo by baseline metformin use. Figure compares semaglutide with placebo. Data-points are proportional to subgroup size. For change in metabolic outcomes, analyses were based on a mixed model for repeated measurements at week 80 (SUSTAIN 6) or week 83 (PIONEER 6), with treatment by subgroup adjusted for baseline value and trial nested within visits. For the safety analyses, number of events per 100 patient-years were analyzed using a negative binomial regression model with a log link and the logarithm of the observation time (100 years) as offset, with treatment by subgroup as fixed factors adjusted by trial. Dashed vertical lines represent lines of null effect (0 for ETDs and 1 for ERRs). ETD/ERR is for semaglutide vs placebo. *Defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or to perform other resuscitative actions. †n-numbers are based on the FAS; the number of subjects included for each analysis was smaller according to data availability. AE adverse event, CI confidence interval, ERR estimated risk ratio, ETD estimated treatment difference, FAS full analysis set, HbA1c glycated hemoglobin, MET metformin, R events per 100 patient-years observed
Fig. 3 Metabolic and safety outcomes with semaglutide vs placebo by baseline metformin use. Figure compares semaglutide with placebo. Data-points are proportional to subgroup size. For change in metabolic outcomes, analyses were based on a mixed model for repeated measurements at week 80 (SUSTAIN 6) or week 83 (PIONEER 6), with treatment by subgroup adjusted for baseline value and trial nested within visits. For the safety analyses, number of events per 100 patient-years were analyzed using a negative binomial regression model with a log link and the logarithm of the observation time (100 years) as offset, with treatment by subgroup as fixed factors adjusted by trial. Dashed vertical lines represent lines of null effect (0 for ETDs and 1 for ERRs). ETD/ERR is for semaglutide vs placebo. *Defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or to perform other resuscitative actions. †n-numbers are based on the FAS; the number of subjects included for each analysis was smaller according to data availability. AE adverse event, CI confidence interval, ERR estimated risk ratio, ETD estimated treatment difference, FAS full analysis set, HbA1c glycated hemoglobin, MET metformin, R events per 100 patient-years observedCC BY · PubMed Central
Fig. 4 Meta-analysis of effect on MACE by baseline metformin: A metformin; B no-metformin; C metformin vs no-metformin. Figures A and B compare a GLP-1RA with placebo. Figure C compares the effect of metformin or no-metformin in GLP-1RA trials. Analyses for SUSTAIN 6 and PIONEER 6 are based on a Cox proportional hazards model with treatment (semaglutide, placebo) by metformin subgroup as fixed factors, stratified by trial and CV risk group (established CVD and/or CKD vs risk factors), and adjusted by baseline variables: sex (male vs female), smoker (current, previous, never), previous MI/stroke/TIA (yes vs no), region (European Union, North America, other), antidiabetic treatment (yes vs no), diabetes duration, eGFR-MDRD and age. Trial duration (median follow-up in years) was: 2.1 (SUSTAIN 6); 1.3 (PIONEER 6); 1.6 (HARMONY OUTCOMES); 3.8 (LEADER); 5.4 (REWIND); 3.2 (EXSCEL); and 1.8 (AMPLITUDE-O). A includes patients receiving metformin; B includes patients not receiving metformin; and C includes the ratio between the hazard ratios for the two different groups, metformin and no-metformin. The fixed-effect model assumes all trials are estimating a common treatment effect; the random-effect model assumes the observed estimates of treatment effect can vary across trials. CI confidence interval, CKD chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, eGFR estimated glomerular filtration rate. GLP-1RA glucagon-like peptide-1 receptor agonist, HR hazard ratio (GLP-1RA vs placebo), I2 inconsistency across estimates, MACE major adverse cardiovascular event, MDRD Modification of Diet in Renal Disease, MI myocardial infarction, RHR ratio between the hazard ratios in metformin vs no-metformin groups, TIA transient ischemic attack
Fig. 4 Meta-analysis of effect on MACE by baseline metformin: A metformin; B no-metformin; C metformin vs no-metformin. Figures A and B compare a GLP-1RA with placebo. Figure C compares the effect of metformin or no-metformin in GLP-1RA trials. Analyses for SUSTAIN 6 and PIONEER 6 are based on a Cox proportional hazards model with treatment (semaglutide, placebo) by metformin subgroup as fixed factors, stratified by trial and CV risk group (established CVD and/or CKD vs risk factors), and adjusted by baseline variables: sex (male vs female), smoker (current, previous, never), previous MI/stroke/TIA (yes vs no), region (European Union, North America, other), antidiabetic treatment (yes vs no), diabetes duration, eGFR-MDRD and age. Trial duration (median follow-up in years) was: 2.1 (SUSTAIN 6); 1.3 (PIONEER 6); 1.6 (HARMONY OUTCOMES); 3.8 (LEADER); 5.4 (REWIND); 3.2 (EXSCEL); and 1.8 (AMPLITUDE-O). A includes patients receiving metformin; B includes patients not receiving metformin; and C includes the ratio between the hazard ratios for the two different groups, metformin and no-metformin. The fixed-effect model assumes all trials are estimating a common treatment effect; the random-effect model assumes the observed estimates of treatment effect can vary across trials. CI confidence interval, CKD chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, eGFR estimated glomerular filtration rate. GLP-1RA glucagon-like peptide-1 receptor agonist, HR hazard ratio (GLP-1RA vs placebo), I2 inconsistency across estimates, MACE major adverse cardiovascular event, MDRD Modification of Diet in Renal Disease, MI myocardial infarction, RHR ratio between the hazard ratios in metformin vs no-metformin groups, TIA transient ischemic attackCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 21

Metadata

Authors
Husain, M., Consoli, A., De Remigis, A., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S.
Affiliations
  • University of Toronto (CA)
  • University of Chieti-Pescara (IT)
  • Novo Nordisk (Denmark) (DK)
  • Swansea University (GB)
Corresponding author
Husain, Mansoor
Venue
Cardiovascular Diabetology
Published
2022-04-28
Volume
21
Issue
1
Pages
64-64
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4225114697
Cited by
16
References
26
Citations by year
2026: 5 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 2
FWCI
2.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Cronfa (Swansea University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
semaglutide, metformin, GLP-1 receptor agonists, type 2 diabetes, major adverse cardiovascular events, cardiovascular outcomes, SUSTAIN 6, Pioneer 6, drug interactions
MeSH terms
Semaglutide, Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Metformin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. https://app.cochat.ai/papers/10.1186/s12933-022-01489-6
The paper
Husain, M., Consoli, A., De Remigis, A., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S. (2022). Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-022-01489-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.